Sangamo Therapeutics Inc  

(Public, NASDAQ:SGMO)   Watch this stock  
Find more results for SGMO
3.65
-0.30 (-7.59%)
Jan 20 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 3.65 - 4.00
52 week 2.65 - 7.60
Open 3.95
Vol / Avg. 1.23M/1.11M
Mkt cap 238.20M
P/E     -
Div/yield     -
EPS -1.08
Shares 70.62M
Beta 3.26
Inst. own 64%
Feb 7, 2017
Q4 2016 Sangamo BioSciences Inc Earnings Release (Estimated) - 4:00PM EST - Add to calendar
Nov 29, 2016
Sangamo BioSciences Inc at Piper Jaffray Healthcare Conference
Nov 17, 2016
Sangamo BioSciences Inc at Jefferies Healthcare Conference
Oct 26, 2016
Q3 2016 Sangamo BioSciences Inc Earnings Call
Oct 26, 2016
Q3 2016 Sangamo BioSciences Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q3 (Sep '16) 2015
Net profit margin -671.80% -102.94%
Operating margin -680.34% -118.51%
EBITD margin - -116.01%
Return on average assets -43.98% -17.68%
Return on average equity -50.07% -20.40%
Employees 119 -
CDP Score - -

Address

501 Canal Blvd
RICHMOND, CA 94804-3559
United States - Map
+1-510-9706000 (Phone)
+1-302-6555049 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Sangamo Therapeutics, Inc., formerly Sangamo BioSciences, Inc., is focused on translating science into genomic therapies that transform patients' lives using the Company's platform technologies in genome editing, gene therapy, gene regulation and cell therapy. The Company has developed technologies available for gene-based therapies. Its product pipeline includes SB-525, SB-FIX, SB-318, SB-913, SB-728-T and SB-728-HSPC. Its zinc finger nuclease (ZFN) in vivo genome editing approach is being evaluated in Phase I/II clinical trials to treat hemophilia B and lysosomal storage disorders mucopolysaccharidosis (MPS) I and MPS II. It is also conducting a Phase I/II clinical trial to evaluate its adeno associated virus (AAV) complementary deoxyribonucleic acid (cDNA) human Factor 8 gene therapy approach, SB-525, to treat hemophilia A. It has investigational new drug application for SB-525. It is also developing ZFN-mediated genome editing-based therapies for blood disorders and cancer.

Officers and directors

Alexander Macrae President, Chief Executive Officer, Director
Bio & Compensation  - Reuters
H. Ward Wolff Chief Financial Officer, Principal Financial and Accounting Officer, Executive Vice President
Age: 67
Bio & Compensation  - Reuters
Dale G. Ando M.D. Vice President - Therapeutic Development, Chief Medical Officer
Age: 60
Bio & Compensation  - Reuters
Edward O. Lanphier II Non-Executive Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
H. Stewart Parker Director
Age: 59
Bio & Compensation  - Reuters
William R. Ringo Jr. Director
Age: 70
Bio & Compensation  - Reuters
Stephen George Dilly MBBS, M.D. Ph.D. Independent Director
Age: 55
Bio & Compensation  - Reuters
John W. Larson Independent Director
Age: 80
Bio & Compensation  - Reuters